NeuroScientific Biopharmaceuticals Ltd (ASX:NSB) (“NeuroScientific” or “the Company”) is pleased to advise that the Company has filed a Pre-Investigation New Drug Application (‘pre IND’) meeting request with the US Food and Drug Administration (‘FDA’) for EmtinB for treatment of advanced glaucoma in adults. The request includes an overview of the proposed non-clinical and clinical programs in glaucoma, as well as specific questions relating to regulatory requirements for progression to the filing of an investigational new drug (‘IND’) application. NeuroScientific expects the meeting to be held within 60 days.
NSB Price at posting:
6.1¢ Sentiment: Buy Disclosure: Held
